Johnson & Johnson has come out fighting after Pfizer announced yesterday that it is ready to launch a biosimilar competitor to its blockbuster Remicade. J&J said it had a “biosimilar ...

Only three studies on nonclinical switching were identified, all of which included infliximab as the initial biologic agent. The rationale for nonclinical switching among TNF antagonists depends ...

Expert Rev Pharmacoeconomics Outcomes Res. 2012;12(3):319-333. The most recent biologic therapy to receive marketing approval, tocilizumab, was evaluated in a 24-week, randomized, placebo ...

The FDA unveiled the Chemical Contaminants Transparency Tool, a searchable online database that provides a list of chemical contaminant types and levels used to evaluate possible harm in foods ...

Other treatment regimens included topical steroid (4 cases, 12.9%), cyclosporine (2 cases, 6.5%), infliximab (2 cases, 6.5%), etanercept (1 case, 3.2%), ruxolitinib (1 patient, 6.5%), ruxolitinib (1 ...